|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1992
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CF02
|
|
gptkbp:brand
|
gptkb:Ambien
gptkb:Edluar
gptkb:Stilnox
gptkb:Intermezzo
|
|
gptkbp:chemicalFormula
|
C19H21N3O
|
|
gptkbp:contraindication
|
sleep apnea
severe liver impairment
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Synthelabo
|
|
gptkbp:drugClass
|
sedative-hypnotic
|
|
gptkbp:duration
|
2-3 hours
|
|
gptkbp:eliminatedIn
|
renal
hepatic
|
|
gptkbp:form
|
gptkb:tablet
extended-release tablet
sublingual tablet
|
|
gptkbp:genericName
|
gptkb:zolpidem
|
|
gptkbp:halfLife
|
2.5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ambien
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:rifampin
gptkb:CNS_depressants
gptkb:ketoconazole
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Sanofi
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Europe
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:onset
|
15 minutes
|
|
gptkbp:overdoseSymptoms
|
coma
respiratory depression
excessive sedation
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionForm
|
oral tablet
|
|
gptkbp:riskFactor
|
abuse
withdrawal
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
memory loss
nausea
dizziness
headache
drowsiness
sleepwalking
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:zolpidem
|
|
gptkbp:bfsLayer
|
6
|